Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 9/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440140 | 0.85 | AVPR1B (0.48) | — | |
| SCHEMBL2204267 | 0.84 | BMP1 (0.41) | BMP1ITGAVITGB3PSMB8MMP1 | |
| SCHEMBL2204271 | 0.84 | BMP1 (0.41) | BMP1ITGAVITGB3PSMB8MMP1 | |
| SCHEMBL6440365 | 0.81 | MMP2 (0.55) | MMP2MMP13MMP1MMP3MMP9 | |
| SCHEMBL4172106 | 0.76 | TDP1 (0.54) | MMP2MMP13ALDH1A1CYP2C19PSMB8 | |
| SCHEMBL14047889 | 0.75 | BMP1 (0.36) | BMP1NR3C1PGRNR3C2 | |
| SCHEMBL8716427 | 0.74 | SLC1A3 (0.51) | MMP2MMP13ALDH1A1CYP2C19ITGB3 | |
| SCHEMBL7448661 | 0.73 | ITGAV (0.59) | ITGAVALDH1A1CYP2C19ITGB3 | |
| SCHEMBL6394294 | 0.73 | ITGAV (0.45) | BMP1ITGAVMMP2ALDH1A1MMP9 | |
| SCHEMBL2204277 | 0.70 | BMP1 (0.46) | BMP1ITGAVPSMB8NR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| EP-2344457-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010049146-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | BMP1 1617/4885ITGAV 1819/4885MMP2 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.